Seasonal Influenza Carries Higher Hospitalization and Death Risk in Inflammatory Joint Disease
Swedish nationwide registry data show that patients with inflammatory joint diseases faced a consistently higher risk of serious seasonal influenza outcomes than the general population, although the excess was modest after accounting for comorbidity burden. Across four influenza seasons from 2015 through 2019, the cohort included 116,989 patients with inflammatory joint disease and matched population comparators. The study also identified 71,556 patients with inflammatory joint disease who were receiving active treatment with conventional synthetic DMARDs, bDMARDs, or tsDMARDs at the start of each influenza season, allowing a separate look at treatment class and infection outcomes.
Per season, the average absolute risk of hospitalization listing influenza was 0.25% in the inflammatory joint disease group and 0.1% in the general population. The crude hazard ratio was 2.38, with a 95% confidence interval of 2.21 to 2.56. After adjustment for comorbidities, the hazard ratio fell to 1.44, with a 95% confidence interval of 1.33 to 1.56. Death listing influenza showed the same pattern: 0.015% in the inflammatory joint disease group versus 0.006% among comparators, with a crude hazard ratio of 2.63 (95% CI 1.93 to 3.58) and an adjusted hazard ratio of 1.46 (95% CI 1.07 to 2.01).
The numbers are small in absolute terms, but the direction is consistent. Patients with inflammatory joint disease enter influenza seasons with a measurable vulnerability that is not fully explained by diagnosis alone. Cardiovascular disease, pulmonary disease, renal disease, frailty, and other chronic conditions often travel with these immune-mediated disorders, and the adjustment-driven drop in hazard ratios suggests that those accompanying illnesses do much of the work in driving severe influenza outcomes.
A single sentence captures the clinical reality: comorbidity, not the rheumatic diagnosis alone, explains much of the risk.
DMARD Exposure Did Not Add Measurable Influenza Risk
Among patients already receiving treatment, the comparison across DMARD classes did not reveal an added seasonal influenza penalty from bDMARDs or tsDMARDs. That finding matters because biologic and targeted synthetic therapies often raise concerns about impaired antiviral defense, especially during respiratory virus season. In this cohort, however, the data do not support the idea that these agents independently increase hospitalization or death related to seasonal influenza beyond the baseline risk associated with inflammatory joint disease itself.
This pattern is biologically plausible. Many patients with inflammatory joint disease receive immunomodulatory therapy because uncontrolled systemic inflammation itself can worsen overall health status, increase organ involvement, and amplify infection-related complications. By reducing inflammatory burden, DMARDs may partially offset some of the physiologic stress that otherwise contributes to severe outcomes. The study does not suggest that immunosuppression is irrelevant, but it does indicate that influenza outcomes in routine care are shaped more by the patient’s broader medical profile than by the choice of advanced DMARD class.
The practical implication is direct at the bedside. Influenza prevention in these patients cannot focus narrowly on whether a given biologic or targeted agent is being used. Risk reduction has to include vaccination, early antiviral treatment when indicated, and attention to the chronic diseases that stack the odds toward hospitalization or death.
Influenza Risk in IJD Remains Lower Than COVID-19, but the Relative Pattern Is Similar
The investigators placed the influenza findings in context by comparing them with earlier COVID-19 data in similar inflammatory joint disease populations. Absolute risks for influenza outcomes were about half those seen with hospitalization for COVID-19 and about one-tenth of those seen with death from COVID-19. Even so, the relative estimates comparing inflammatory joint disease with the general population were similar across the two infections.
This comparison is clinically important because it separates two different questions. One asks how dangerous each virus is in absolute terms. The answer is clear: COVID-19 produced the larger burden. The other asks whether inflammatory joint disease confers a roughly comparable relative vulnerability across respiratory viral infections. Here, the answer also points in the same direction. Patients with inflammatory joint disease faced about a 50% to 100% increase in risk for serious outcomes with both infections, and much of that excess came from the comorbidity profile rather than the rheumatic diagnosis alone.
For clinicians, that distinction supports a risk-stratified preventive strategy. The patient with rheumatoid arthritis, psoriatic arthritis, or another inflammatory joint disease who also carries multiple cardiopulmonary comorbidities should be viewed as vulnerable during influenza season, even if current DMARD therapy is not itself driving additional risk. The viral trigger changes, but the host factors remain the same.
The absolute event rates remain low, and that should temper alarm. Yet low absolute risk does not equal negligible risk in a population managed across millions of encounters. Even small seasonal differences translate into preventable hospitalizations when exposure is widespread and the patient population is medically complex.
What the Registry Data Can and Cannot Prove
Swedish registry studies offer a major strength: broad, real-world coverage across an entire health system, with enough scale to estimate rare outcomes such as influenza-related death. They also carry the familiar limits of observational research. Residual confounding is always possible, especially when comorbidity patterns are central to the outcome. Influenza coding can also reflect cases where the virus is listed among several contributing diagnoses rather than isolated as a single cause of hospitalization or death.
Even with those limits, the signal is coherent. Influenza posed a higher risk to patients with inflammatory joint disease than to the general population, and the elevation shrank after accounting for comorbidity burden. Advanced DMARD therapy did not add measurable risk for hospitalization or death related to seasonal influenza. In practical terms, prevention should be organized around the patient’s total medical load, not around alarm over biologic or targeted therapy alone.
The remaining gap is not whether influenza matters in inflammatory joint disease. It clearly does. The open question is how best to translate this risk profile into more precise prevention, vaccination, and early treatment strategies for the patients who carry the most comorbidity and the least physiologic reserve.